Stem Cell Therapeutics Corp. Announces Presentation by Dr. Joshua M. Hare on NTx-265(R) Animal Data After Post-Myocardial Infarc
March 30 2009 - 8:40AM
Marketwired
Stem Cell Therapeutics Corp. (the "Company" or "SCT") (TSX VENTURE:
SSS) announced today that Dr. Joshua M. Hare, MD, FACC, Louis
Lemberg Professor of Medicine and Director, Interdisciplinary Stem
Cell Institute (ISCI) at the University of Miami, presented the
"Effects of Combination of Proliferative Agents and Erythropoeitin
(EPO) on Left Ventricular Remodeling Post-Myocardial Infarction" at
the 58th Annual American College of Cardiology Conference in
Orlando, Florida.
The study, conducted by Dr. Hare's team at the University of
Miami, described the effects of two drug regimens: human Chorionic
Gonadotropin (hCG) plus EPO (NTx-265� regimen) and a regimen
composed of prolactin (PRL) then EPO. Both of the regimens were
dosed in a similar manner, following a severe left ventricular
coronary occlusion - heart attack - in rats.
The study demonstrated that after a severe myocardial infarction
(MI), the left ventricle chamber dimension increased by
approximately 200% and decreased in ejection fraction by about 44%.
Systemic treatment with hCG, EPO or hCG plus EPO (NTx-265� regimen)
significantly limited the expansion of ventricular chamber
dimension and reversed the effects on ejection fraction by
approximately 50%. Prolactin, however, did not have this
effect.
Dr. Hare concluded "that hCG alone or in combination with EPO
may be an effective therapeutic strategy to ameliorate post-MI
remodeling. The absence of this same effect with PRL suggests a
direct effect of on NTx-265� on the myocardium." Moreover, Dr. Hare
also believes that "given the established safety profile of hCG in
humans, clinical trials may be warranted as a next step."
Dr. Alan Moore, President and CEO, commented as follows:
"This recently completed study by Dr. Hare builds upon earlier
observations that NTx-265� modulates the activity of a population
of cells within the adult heart. We are pleased to now have the
confirmation of a long suspected positive effect on recovery
following heart attack. The exciting, novel study results suggest
that an entirely new therapeutic drug approach may be possible in
the heart and emphasizes the enormous potential that is captured
within SCT's patent portfolio."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX VENTURE: SSS)
focused on the development and commercialization of drug-based
therapies to treat central nervous system diseases. SCT is a leader
in the development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The Company's programs aim to
repair neurological function lost due to disease or injury. SCT's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 Email: amoore@stemcellthera.com Stem
Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations
(403) 245-5495 ext. 221 Email: crampton@stemcellthera.com Website:
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024